fined as severe when the mean transvalvular pressure gradient is $40 mm Hg and the valve area is reduced below 1 cm 2 (<0.8 cm 2 for more specificity) (1) .
Because of the dependency of gradients on flow, LGSAS and preserved EF that summarizes the current knowledge of this entity and its implications as to the patient substrate, prognosis, and management.
THE STUDY
The meta-analysis comprises 18 studies within the past 10 years, in which either overall mortality of LGSAS with preserved EF and its outcome, an interesting and challenging clinical scenario.
LGSAS Dr. Zoghbi has reported that he has no relationships relevant to the contents of this paper to disclose. Of interest, in the current study, the high prevalence of comorbidities in this population was similar to those with low-flow LGSAS and may in part account for the comparable prognosis of these 2 patient populations. Ascertaining severity of AS in LGSAS is crucial for patient management; asymptomatic patients can be managed medically until symptoms arise, because their prognosis may be similar to moderate AS in the setting of lesser AS severity and fewer comorbidities (7).
EFFECT OF AVR ON PROGNOSIS IN LGSAS
AVR in patients with SAS improves survival in symptomatic patients. In the current study, AVR improved survival compared with conservative therapy in patients with LGSAS (low and normal flow);
however, patients with high-gradient SAS, who also had fewer comorbidities, had the greatest benefit.
With the limitations to the studies already noted, the question is whether the survival benefit is over- In the meta-analysis, studies that included patients with moderate AS (valve area >1 cm 2 ) raise a concern of patient selection: 59% had symptoms similar to or higher than those with SAS, and 35% of them underwent AVR. This is an unusually high prevalence of symptoms and AVR in moderate AS and should not be 
